The Federal Trade Commission issued warning letters to several companies that marketed an unproven drug to treat COVID-19. Sales of the nonapproved drug, thymosin alpha-1, were first reported by NPR.

An NPR investigation has identified a web of more than 30 medical practices and compounding pharmacies in over a dozen states that have made claims about thymosin alpha-1 online and on social media.